- Home
- DSGX vs QGEN Comparison
DSGX vs QGEN Comparison
Compare DSGX & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DSGX | QGEN |
|---|---|---|
| Founded | 1981 | 1986 |
| Country | Canada | Netherlands |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 10.2B |
| IPO Year | 1999 | 1996 |
Fundamental Metrics
Financial Performance| Metric | DSGX | QGEN |
|---|---|---|
| Price | $90.68 | $45.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 7 |
| Target Price | ★ $119.40 | $49.74 |
| AVG Volume (30 Days) | 518.3K | ★ 1.2M |
| Earning Date | 12-03-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 3.37% |
| EPS Growth | 12.65 | ★ 331.20 |
| EPS | 1.78 | ★ 1.84 |
| Revenue | $703,706,000.00 | ★ $2,070,781,000.00 |
| Revenue This Year | $11.82 | $7.12 |
| Revenue Next Year | $11.25 | $6.13 |
| P/E Ratio | $50.95 | ★ $24.71 |
| Revenue Growth | ★ 11.39 | 5.32 |
| 52 Week Low | $78.88 | $37.63 |
| 52 Week High | $124.31 | $51.88 |
Technical Indicators
Market Signals| Indicator | DSGX | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 56.84 | 42.22 |
| Support Level | $91.58 | $45.55 |
| Resistance Level | $94.13 | $47.48 |
| Average True Range (ATR) | 2.16 | 0.59 |
| MACD | 1.34 | -0.17 |
| Stochastic Oscillator | 68.87 | 11.63 |
Price Performance
Historical ComparisonAbout DSGX Descartes Systems Group Inc. (The)
Descartes Systems Group provides a software solution that allows users in the shipping industry to communicate with one another. Its core product is the Global Logistics Network, which is best understood as transaction-driven. Descartes charges clients to send/receive messages, data, and documents on the GLN. Customers typically contract for a monthly minimum over a multiyear period. The GLN platform allows Descartes to upsell additional software modules as well, typically provided via a software-as-a-service model.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).